Teva, 2 others sue Aurobindo Pharma for alleged infringement of cancer drug Bendeka
Teva filed a probable patent infringement petition on May 11 against Aurobindo in the US district court for the District of Delaware on 28 counts.;
Hyderabad: Teva Pharmaceuticals, along with Cephalon Inc and Eagle Pharmaceuticals, has filed a petition in a US court against Aurobindo Pharma alleging that the Indian drug-maker is planning to come out with a generic version of Bendeka, a cancer medicine, before the expiration of its patents.
Bendeka (bendamustine hydrochloride) is indicated for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.
Eagle, the patent-holder, has provided a license to Cephalon the right to sue for infringement of the drug and in 2015, Cephalon assigned its rights to Teva Pharmaceuticals.
Teva filed a probable patent infringement petition on May 11 against Aurobindo in the US district court for the District of Delaware on 28 counts.
Also Read: Teva Pharmaceutical To Buy Mexican Drugmaker
On April 6, Aurobindo Pharma had sent a letter (notice letter) to Teva saying that it had submitted US FDA an Abbreviated New Drug Application (ANDA) with paragraph IV certifications to make copycat version before expatriation of the patents of Bendeka Injection, 100 mg/4 mL (25 mg/mL), the petition said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.